SUNRISE, Fla. and CLEVELAND, Feb. 26, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Bioheart, Inc., a biotechnology company focused on the development of innovative cell therapies for the treatment of heart attacks, announced today that it has provided an unrestricted research grant to the Ohio Cell-based Therapy Consortium (OCTC) in the amount of $100,000. The OCTC was established by the Center for Stem Cell and Regenerative Medicine (CSCRM, http://stemcellcenter.case.edu) and the National Center for Regenerative Medicine (NCRM, www.ncrm.us), both of Cleveland, OH, and consists of a statewide network of clinician researchers at key Ohio institutions. The first working group, the OCTC-Cardiovascular, is focusing on translational cardiovascular clinical applications with Daniel I. Simon M.D. of University Hospitals Case Medical Center serving as Director and Marc Penn, M.D., Ph.D., of the Cleveland Clinic serving as Associate Director.
